Study Title

Subjects will be treated in cohorts at three sequential target absorbed radiation dose levels, where the dose level for the next cohort will be determined by a prespecified decision tree for escalation/de-escalation, according to the accelerated Time-to-Event Bayesian Optimal Interval Design (TITE-BOIN) approach.

Study Details

Description:

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

Sponsor:

Boston Scientific Corporation

Contacts:

McAnthony Tarway

mcanthony.tarway@bsci.com

615-580-1320

Shirley Nyepah

shirley.nyepah@bsci.com

612-300-7205

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468